Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
D Koeberle, J-F Dufour, G Demeter, Q Li, K Ribi, P Samaras, P Saletti, A D Roth, D Horber, M Buehlmann, A D Wagner, M Montemurro, G Lakatos, J Feilchenfeldt, M Peck-Radosavljevic, D Rauch, B Tschanz, G Bodoky, Swiss Group for Clinical Cancer Research (SAKK), D Koeberle, J-F Dufour, G Demeter, Q Li, K Ribi, P Samaras, P Saletti, A D Roth, D Horber, M Buehlmann, A D Wagner, M Montemurro, G Lakatos, J Feilchenfeldt, M Peck-Radosavljevic, D Rauch, B Tschanz, G Bodoky, Swiss Group for Clinical Cancer Research (SAKK)
Abstract
Background: Sorafenib (S), a multitargeted tyrosine kinase inhibitor, is the standard of care for first-line systemic treatment of advanced hepatocellular carcinoma (HCC). Everolimus (E) is a potent inhibitor of mTOR, a pathway frequently activated in HCC. Preclinical data suggest that the combination S + E has additive effects compared with single-agent S.
Patients and methods: Patients with unresectable or metastatic HCC and Child-Pugh ≤7 liver dysfunction were randomized to receive daily S 800 mg alone or with E 5 mg until progression or unacceptable toxicity. The primary end point was progression-free survival at 12 weeks (PFS12). The secondary end points included response rate, PFS, time to progression (TTP), overall survival (OS), duration of disease stabilization (DDS), safety, and quality-of-life (QoL) assessments.
Results: A total of 106 patients were randomized: 46 patients received S and 60 patients received S + E. Ninety-three patients were assessable for the primary end point and 105 patients for the safety analysis. The PFS12 rate was 70% [95% confidence interval (CI) 54-83] and 68% (95% CI 53-81) in patients randomized to S and S + E, respectively. The RECIST (mRECIST) response rate was 0% (23%) in the S arm and 10% (35%) in the S + E arm. Median PFS (6.6 versus 5.7 months), TTP (7.6 versus 6.3 months), DDS (6.7 versus 6.7 months), and OS (10 versus 12 months) were similar in the S and S + E arms, respectively. Grade 3/4 adverse events occurred in 72% and 86% of patients in arm S and arm S + E, respectively. Patients had similar QoL scores over time, except for a greater worsening in physical well-being and mood in the arm S + E.
Conclusions: No evidence was found that S + E improves the efficacy compared with S alone. Combining 5 mg E with full-dose S is feasible, but more toxic than S alone. Further testing of this drug combination in molecularly unselected HCCs appears unwarranted.
Clinicaltrialsgov: NCT01005199.
Keywords: everolimus; hepatocellular carcinoma; sorafenib; tyrosine kinase inhibitor.
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Source: PubMed